Results 151 to 160 of about 4,912,345 (213)

PDE10A Inhibition in Schizophrenia: A Randomised, Placebo-Controlled Phase 2 Study of Alofropodect (CPL'36) in Patients Experiencing Acute Schizophrenia. [PDF]

CNS Drugs
Wieczorek M, Waszkiewicz N, Gromniak-Haniecka E, Réthelyi JM, Pustovoyt M, Filts Y, Blazhevych Y, Matłoka M, Janowska S, Łapińska B, Rudzki PJ, Jaźwiec R, Sierzputowska-Prarat J.   +12 more
europepmc   +1 more source

Neurological Adverse Effects of Antipsychotic Medication in Children and Young People. [PDF]

Paediatr Drugs
Besag FMC, Vasey MJ, Hollis C, Taylor D.
europepmc   +1 more source

Benzodiazepine use in schizophrenia: A review of the literature. [PDF]

Ment Health Clin
Noel C, Maclay C.
europepmc   +1 more source

Safety of Short-T erm Low-Dose Olanzapine in Patients with Cancer and Diabetes Receiving Cisplatin-Based Chemotherapy: A Retrospective TriNetX Cohort Study. [PDF]

Drug Des Devel Ther
Hayashi T, Shiraishi C, Abe M, Kaneshige S, Egawa T.   +4 more
europepmc   +1 more source

Trip killers: Addressing a critical knowledge gap in psychedelic research. [PDF]

J Psychopharmacol
O'Mahony B, Harrington C, Harkin A, Lally N.   +3 more
europepmc   +1 more source

Solutions to common issues in the use of LAIs. [PDF]

CNS Spectr
Saklad SR.
europepmc   +1 more source

Prolonged Tardive Dyskinesia Induced by Long-Acting Paliperidone Palmitate in Schizophrenia: A Case Report. [PDF]

Am J Case Rep
Chen YM, Chang S.
europepmc   +1 more source

Prevalence, severity and predictors of Antipsychotic-Related Adverse Drug Reactions at the Psychiatry Clinic of a Regional Referral Hospital in Uganda. [PDF]

PLoS One
Tumwebaza JM, Bukke SPN, Narapureddy BR, Kabera RM, Sebisaalu J, Abubakar A, Kitheka PM, Nimusiima G, Mohamed AOA, Muwanguzi M, Ashaba S, Yadesa TM.   +11 more
europepmc   +1 more source